{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:18:56Z","timestamp":1793305136857,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"An anonymous donor funded this project."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mood dysfunction is highly prevalent in Parkinson\u2019s disease (PD), a main predictor of functional decline, and difficult to treat\u2014novel interventions are critically needed. Psilocybin shows early promise for treating depression and anxiety, but its potential in PD is unknown, as safety concerns have excluded people with neurodegenerative disease from previous trials. In this open-label pilot (NCT04932434), we examined the feasibility of psilocybin therapy among people with mild to moderate stage PD plus depression and\/or anxiety. 12 participants (mean age 63.2\u2009\u00b1\u20098.2 years, 5 women) received psilocybin (one 10\u2009mg followed by one 25\u2009mg dose) with psychotherapy. There were no serious adverse events, no medical interventions required to manage effects of psilocybin, and no exacerbation of psychosis. Ten participants experienced treatment-emergent adverse events; the most frequent were anxiety, nausea, and increased blood pressure. We observed no worsening of PD symptomology measured by the Movement Disorder Society Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS). On the contrary, non-motor (MDS-UPDRS\u00a0Part I: \u201313.8\u2009\u00b1\u20091.3,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001, Hedges\u2019\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20093.0) and motor symptoms (Part II: \u20137.5\u2009\u00b1\u20090.9,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20091.2; Part III: \u20134.6\u2009\u00b1\u20091.3,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001;\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20090.3) as well as performance in select cognitive domains (Paired Associates Learning [-0.44\u2009\u00b1\u20090.14,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.003,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20090.4], Spatial Working Memory [\u20130.52\u2009\u00b1\u20090.17,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20090.7], and Probabilistic Reversal Learning [2.9\u2009\u00b1\u20090.9,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20091.3]) improved post-treatment, and improvements were sustained until the final safety assessment one month following drug exposure. Baseline Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A) scores were 21.0\u2009\u00b1\u20098.7 and 17.0\u2009\u00b1\u20093.7, respectively. Both improved to a clinically meaningful degree post-treatment; these improvements persisted to the final assessment three months following drug exposure\u00a0(MADRS: -9.3\u2009\u00b1\u20092.7,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009.001,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20091.0; HAM-A: \u20133.8\u2009\u00b1\u20091.7;\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.031,\n                    <jats:italic>g<\/jats:italic>\n                    \u2009=\u20090.7). This study provides the first data on psilocybin\u2019s effects in any neurodegenerative disease. Results suggest that psilocybin therapy in PD warrants further investigation.\n                  <\/jats:p>","DOI":"10.1038\/s41386-025-02097-0","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T18:47:38Z","timestamp":1744224458000},"page":"1200-1209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial"],"prefix":"10.1038","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6787-1490","authenticated-orcid":false,"given":"Ellen R.","family":"Bradley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Fernandes-Osterhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Szigeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill L.","family":"Ostrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith A.","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiah","family":"Llerena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Finley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Rafael P.","family":"Zuzuarregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Busby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"McKernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5552-7078","authenticated-orcid":false,"given":"Andrew D.","family":"Penn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliss C. C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond C.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Woolley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2097_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12264-022-00934-6","volume":"39","author":"HN Costa","year":"2023","unstructured":"Costa HN, Esteves AR, Empadinhas N, Cardoso SM. Parkinson\u2019s disease: a multisystem disorder. Neurosci Bull. 2023;39:113\u201324.","journal-title":"Neurosci Bull"},{"key":"2097_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939\u201353.","journal-title":"Lancet Neurol"},{"key":"2097_CR3","doi-asserted-by":"crossref","unstructured":"Jellinger KA. Neuropathology of nonmotor symptoms of Parkinson\u2019s disease. Int. Rev. Neurobiol., vol. 133, Elsevier; 2017. p. 13\u201362.","DOI":"10.1016\/bs.irn.2017.05.005"},{"key":"2097_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435\u201350.","journal-title":"Nat Rev Neurosci"},{"key":"2097_CR5","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1532-5415.2004.52219.x","volume":"52","author":"D Weintraub","year":"2004","unstructured":"Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson\u2019s disease. J Am Geriatr Soc. 2004;52:784\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"2097_CR6","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/mdc3.12205","volume":"2","author":"D Bega","year":"2015","unstructured":"Bega D, Luo S, Fernandez H, Chou K, Aminoff M, Parashos S, et al. Impact of depression on progression of impairment and disability in early Parkinson\u2019s disease. Mov Disord Clin Pr. 2015;2:371\u20138.","journal-title":"Mov Disord Clin Pr"},{"key":"2097_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(16)30328-3","volume":"16","author":"A Schrag","year":"2017","unstructured":"Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol. 2017;16:66\u201375.","journal-title":"Lancet Neurol"},{"key":"2097_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neubiorev.2015.11.014","volume":"61","author":"JMT van Uem","year":"2016","unstructured":"van Uem JMT, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, et al. Health-related quality of life in patients with Parkinson\u2019s disease\u2014A systematic review based on the ICF model. Neurosci Biobehav Rev. 2016;61:26\u201334.","journal-title":"Neurosci Biobehav Rev"},{"key":"2097_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease-an evidence-based medicine review. Mov Disord J Mov Disord Soc. 2019;34:180\u201398.","journal-title":"Mov Disord J Mov Disord Soc"},{"key":"2097_CR10","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl J Med. 2022;387:1637\u201348.","journal-title":"N. Engl J Med"},{"key":"2097_CR11","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jama.2023.14530","volume":"330","author":"CL Raison","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA. 2023;330:843\u201353.","journal-title":"JAMA"},{"key":"2097_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol Oxf Engl. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2097_CR13","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol (Oxf). 2016;30:1165\u201380.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"2097_CR14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharm Rev. 2016;68:264\u2013355.","journal-title":"Pharm Rev"},{"key":"2097_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/03602532.2016.1278228","volume":"49","author":"RJ Dinis-Oliveira","year":"2017","unstructured":"Dinis-Oliveira RJ. Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance. Drug Metab Rev. 2017;49:84\u201391.","journal-title":"Drug Metab Rev"},{"key":"2097_CR16","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.neubiorev.2019.12.001","volume":"108","author":"RG dos Santos","year":"2020","unstructured":"dos Santos RG, Hallak JEC. Therapeutic use of serotoninergic hallucinogens: a review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev. 2020;108:423\u201334.","journal-title":"Neurosci Biobehav Rev"},{"key":"2097_CR17","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep."},{"key":"2097_CR18","doi-asserted-by":"publisher","first-page":"117906951880050","DOI":"10.1177\/1179069518800508","volume":"12","author":"DE Olson","year":"2018","unstructured":"Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508.","journal-title":"J Exp Neurosci"},{"key":"2097_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2015.00358","volume":"6","author":"A Szabo","year":"2015","unstructured":"Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. Front Immunol. 2015;6:358.","journal-title":"Front Immunol"},{"key":"2097_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","volume":"48","author":"AE Calder","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48:104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"2097_CR21","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s00702-022-02559-5","volume":"129","author":"KA Jellinger","year":"2022","unstructured":"Jellinger KA. The pathobiological basis of depression in Parkinson disease: challenges and outlooks. J Neural Transm. 2022;129:1397\u2013418.","journal-title":"J Neural Transm"},{"key":"2097_CR22","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.neubiorev.2018.10.004","volume":"96","author":"F Faivre","year":"2019","unstructured":"Faivre F, Joshi A, Bezard E, Barrot M. The hidden side of Parkinson\u2019s disease: studying pain, anxiety and depression in animal models. Neurosci Biobehav Rev. 2019;96:335\u201352.","journal-title":"Neurosci Biobehav Rev"},{"key":"2097_CR23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1093\/brain\/aww162","volume":"139","author":"A Maillet","year":"2016","unstructured":"Maillet A, Krack P, Lhomm\u00e9e E, M\u00e9t\u00e9reau E, Klinger H, Favre E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson\u2019s disease. Brain J Neurol. 2016;139:2486\u2013502.","journal-title":"Brain J Neurol"},{"key":"2097_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","volume":"102","author":"CPC Galts","year":"2019","unstructured":"Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, et al. Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev. 2019;102:56\u201384.","journal-title":"Neurosci Biobehav Rev"},{"key":"2097_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106434","volume":"83","author":"IP Mendon\u00e7a","year":"2020","unstructured":"Mendon\u00e7a IP, Duarte-Silva E, Chaves-Filho AJM, Andrade da Costa BL, da S, Peixoto CA. Neurobiological findings underlying depressive behavior in Parkinson\u2019s disease: A review. Int Immunopharmacol. 2020;83:106434.","journal-title":"Int Immunopharmacol"},{"key":"2097_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM. The pharmacology of psilocybin. Addict Biol. 2002;7:357\u201364.","journal-title":"Addict Biol"},{"key":"2097_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.nbd.2011.10.025","volume":"46","author":"S Jain","year":"2012","unstructured":"Jain S, Goldstein DS. Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis. Neurobiol Dis. 2012;46:572\u201380.","journal-title":"Neurobiol Dis"},{"key":"2097_CR28","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2016;26:1327\u201337.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"2097_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00221-013-3621-2","volume":"230","author":"P Huot","year":"2013","unstructured":"Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson\u2019s disease. Exp Brain Res. 2013;230:463\u201376.","journal-title":"Exp Brain Res"},{"key":"2097_CR30","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneurol.2010.166","volume":"67","author":"EB Forsaa","year":"2010","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010;67:996\u20131001.","journal-title":"Arch Neurol"},{"key":"2097_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga J, Martinez-Horta S, Fern\u00e1ndez de Bobadilla R, P\u00e9rez J, Ribosa-Nogu\u00e9 R, Mar\u00edn J, et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov Disord J Mov Disord Soc. 2016;31:45\u201352.","journal-title":"Mov Disord J Mov Disord Soc"},{"key":"2097_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tips.2008.06.006","volume":"29","author":"MA Geyer","year":"2008","unstructured":"Geyer MA, Vollenweider FX. Serotonin research: contributions to understanding psychoses. Trends Pharm Sci. 2008;29:445\u201353.","journal-title":"Trends Pharm Sci"},{"key":"2097_CR33","doi-asserted-by":"publisher","unstructured":"Simonsson O, Mosing MA, Osika W, Ull\u00e9n F, Larsson H, Lu Y, et al. Adolescent psychedelic use and psychotic or manic symptoms. JAMA Psychiatry. 2024. 13 March 2024. https:\/\/doi.org\/10.1001\/jamapsychiatry.2024.0047.","DOI":"10.1001\/jamapsychiatry.2024.0047"},{"key":"2097_CR34","doi-asserted-by":"publisher","unstructured":"Simonsson O, Goldberg SB, Chambers R, Osika W, Simonsson C, Hendricks PS Psychedelic use and psychiatric risks. Psychopharmacology (Berl). 2023. 24 October 2023. https:\/\/doi.org\/10.1007\/s00213-023-06478-5.","DOI":"10.1007\/s00213-023-06478-5"},{"key":"2097_CR35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1176\/appi.ajp.22010073","volume":"179","author":"G Barber","year":"2022","unstructured":"Barber G, Nemeroff CB, Siegel S. A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability. Am J Psychiatry. 2022;179:892\u20136.","journal-title":"Am J Psychiatry"},{"key":"2097_CR36","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1001\/archneurol.2010.35","volume":"67","author":"Ballanger","year":"2010","unstructured":"Ballanger, Strafella B, Eimeren AP, van T, Zurowski M, Rusjan PM, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010;67:416\u201321.","journal-title":"Arch Neurol"},{"key":"2097_CR37","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2010;35:881\u201392.","journal-title":"Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol"},{"key":"2097_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1212\/01.WNL.0000031424.51127.2B","volume":"60","author":"M Doder","year":"2003","unstructured":"Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. 11C-WAY 100635 PET study. Tremor in Parkinson\u2019s disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. 2003;60:601\u20135.","journal-title":"Neurology"},{"key":"2097_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1353-8020(02)00011-1","volume":"9","author":"PH Gordon","year":"2002","unstructured":"Gordon PH, Pullman SL, Louis ED, Frucht SJ, Fahn S. Mirtazapine in Parkinsonian tremor. Parkinsonism Relat Disord. 2002;9:125\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"2097_CR40","doi-asserted-by":"crossref","unstructured":"Kohl Z, Winkler J Chapter 50 - Serotonin in Parkinson\u2019s disease. In: M\u00fcller CP, Cunningham KA, editors. Handb. Behav. Neurosci., vol. 31, Elsevier; 2020. p. 969-79.","DOI":"10.1016\/B978-0-444-64125-0.00050-5"},{"key":"2097_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1468-1331.9.s3.1.x","volume":"9","author":"SL Nicholson","year":"2002","unstructured":"Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson\u2019s disease \u2013 opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur J Neurol. 2002;9:1\u20136.","journal-title":"Eur J Neurol"},{"key":"2097_CR42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in Parkinson\u2019s disease: a meta-analysis of positron emission tomography studies. Ann Neurol. 2017;81:171\u201380.","journal-title":"Ann Neurol"},{"key":"2097_CR43","doi-asserted-by":"crossref","unstructured":"Grandjean J, Buehlmann D, Buerge M, Sigrist H, Seifritz E, Vollenweider FX, et al. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice: Psilocybin affects resting-state networks in mice. NeuroImage. 2021;225:117456.","DOI":"10.1016\/j.neuroimage.2020.117456"},{"key":"2097_CR44","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670\u201383.","journal-title":"JAMA"},{"key":"2097_CR45","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Pub; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2097_CR46","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1212\/WNL.60.3.360","volume":"60","author":"GF Wooten","year":"2003","unstructured":"Wooten GF. Agonists vs levodopa in PD. Neurology. 2003;60:360\u20132.","journal-title":"Neurology"},{"key":"2097_CR47","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol Oxf Engl. 2008;22:603\u201320.","journal-title":"J Psychopharmacol Oxf Engl"},{"key":"2097_CR48","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1176\/appi.ajp.20230884","volume":"182","author":"N Kirli\u0107","year":"2025","unstructured":"Kirli\u0107 N, Lennard-Jones M, Atli M, Malievskaia E, Modlin NL, Peck SK, et al. Compass psychological support model for COMP360 psilocybin treatment of serious mental health conditions. Am J Psychiatry. 2025;182:126\u201332.","journal-title":"Am J Psychiatry"},{"key":"2097_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998;31:80\u201384.","journal-title":"Pharmacopsychiatry"},{"key":"2097_CR50","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.parkreldis.2013.05.017","volume":"19","author":"C Rodriguez-Blazquez","year":"2013","unstructured":"Rodriguez-Blazquez C, Rojo-Abuin JM, Alvarez-Sanchez M, Arakaki T, Bergareche-Yarza A, Chade A, et al. The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19:889\u201393.","journal-title":"Parkinsonism Relat Disord"},{"key":"2097_CR51","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/mds.25671","volume":"28","author":"AE Lang","year":"2013","unstructured":"Lang AE, Eberly S, Goetz CG, Stebbins G, Oakes D, Marek K, et al. Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments. Mov Disord. 2013;28:1980\u20136.","journal-title":"Mov Disord"},{"key":"2097_CR52","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord J Mov Disord Soc. 2008;23:2129\u201370.","journal-title":"Mov Disord J Mov Disord Soc"},{"key":"2097_CR53","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","volume":"168","author":"K Posner","year":"2011","unstructured":"Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266\u201377.","journal-title":"Am J Psychiatry"},{"key":"2097_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2018.04.008","volume":"54","author":"CV Kulick","year":"2018","unstructured":"Kulick CV, Montgomery KM, Nirenberg MJ. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2018;54:40\u201345.","journal-title":"Parkinsonism Relat Disord"},{"key":"2097_CR55","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.parkreldis.2012.10.022","volume":"19","author":"T Voss","year":"2013","unstructured":"Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H. Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2013;19:295\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"2097_CR56","unstructured":"CANTAB\u00ae [Cognitive assessment software]. 2019. 2019."},{"key":"2097_CR57","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1093\/brain\/124.12.2503","volume":"124","author":"R Cools","year":"2001","unstructured":"Cools R, Barker RA, Sahakian BJ, Robbins TW. Mechanisms of cognitive set flexibility in Parkinson\u2019s disease. Brain. 2001;124:2503\u201312.","journal-title":"Brain"},{"key":"2097_CR58","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1176\/ajp.156.5.780","volume":"156","author":"EP Merriam","year":"1999","unstructured":"Merriam EP, Thase ME, Haas GL, Keshavan MS, Sweeney JA. Prefrontal cortical dysfunction in depression determined by wisconsin card sorting test performance. Am J Psychiatry. 1999;156:780\u20132.","journal-title":"Am J Psychiatry"},{"key":"2097_CR59","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.neuroscience.2009.07.033","volume":"163","author":"DA Peterson","year":"2009","unstructured":"Peterson DA, Elliott C, Song DD, Makeig S, Sejnowski TJ, Poizner H. Probabilistic reversal learning is impaired in Parkinson\u2019s disease. Neuroscience. 2009;163:1092\u2013101.","journal-title":"Neuroscience"},{"key":"2097_CR60","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1037\/npe0000026","volume":"7","author":"A Waegeman","year":"2014","unstructured":"Waegeman A, Declerck CH, Boone C, Seurinck R, Parizel PM. Individual differences in behavioral flexibility in a probabilistic reversal learning task: An fMRI study. J Neurosci Psychol Econ. 2014;7:203\u201318.","journal-title":"J Neurosci Psychol Econ"},{"key":"2097_CR61","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1176\/jnp.12.2.233","volume":"12","author":"DI Kaufer","year":"2000","unstructured":"Kaufer DI, Cummings JL, Ketchel P, Smith V, MacMillan A, Shelley T, et al. Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci. 2000;12:233\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2097_CR62","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry J Ment Sci. 1979;134:382\u20139.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"2097_CR63","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","volume":"14","author":"W Maier","year":"1988","unstructured":"Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders. J Affect Disord. 1988;14:61\u201368.","journal-title":"J Affect Disord"},{"key":"2097_CR64","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N. Engl J Med. 2021;384:1402\u201311.","journal-title":"N. Engl J Med"},{"key":"2097_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2017","unstructured":"Holden SK, Finseth T, Sillau SH, Berman BD. Progression of MDS\u2010UPDRS scores over five years in de novo Parkinson disease from the Parkinson\u2019s progression markers initiative cohort. Mov Disord Clin Pr. 2017;5:47\u201353.","journal-title":"Mov Disord Clin Pr"},{"key":"2097_CR66","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jama.2014.13128","volume":"312","author":"AE McGlothlin","year":"2014","unstructured":"McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. JAMA. 2014;312:1342\u20133.","journal-title":"JAMA"},{"key":"2097_CR67","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.parkreldis.2015.10.006","volume":"21","author":"K Horv\u00e1th","year":"2015","unstructured":"Horv\u00e1th K, Aschermann Z, \u00c1cs P, Deli G, Janszky J, Komoly S, et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015;21:1421\u20136.","journal-title":"Parkinsonism Relat Disord"},{"key":"2097_CR68","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/mds.26960","volume":"32","author":"K Horv\u00e1th","year":"2017","unstructured":"Horv\u00e1th K, Aschermann Z, Kov\u00e1cs M, Makkos A, Harmat M, Janszky J, et al. Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson\u2019s disease rating scale. Mov Disord J Mov Disord Soc. 2017;32:789\u201393.","journal-title":"Mov Disord J Mov Disord Soc"},{"key":"2097_CR69","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/bmjebm-2020-111600","volume":"27","author":"MP Hengartner","year":"2022","unstructured":"Hengartner MP, Pl\u00f6derl M. Estimates of the minimal important difference to evaluate the clinical significance of antidepressants in the acute treatment of moderate-to-severe depression. BMJ Evid-Based Med. 2022;27:69\u201373.","journal-title":"BMJ Evid-Based Med"},{"key":"2097_CR70","doi-asserted-by":"publisher","first-page":"e2232133","DOI":"10.1001\/jamanetworkopen.2022.32133","volume":"5","author":"J Fan","year":"2022","unstructured":"Fan J, Lu W, Tan W, Liu X, Wang Y, Wang N, et al. Effectiveness of acupuncture for anxiety among patients with Parkinson disease: a randomized clinical trial. JAMA Netw Open. 2022;5:e2232133.","journal-title":"JAMA Netw Open"},{"key":"2097_CR71","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1177\/02698811221116926","volume":"36","author":"JJ Breeksema","year":"2022","unstructured":"Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol (Oxf). 2022;36:1100\u201317.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"2097_CR72","doi-asserted-by":"crossref","unstructured":"McDaniels B, Pontone GM, Keener AM, Subramanian I. A prescription for wellness in early PD: just what the doctor ordered. J Geriatr Psychiatry Neurol. 2023:08919887231164358.","DOI":"10.1177\/08919887231164358"},{"key":"2097_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01706-y","volume":"11","author":"MK Doss","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11:1\u201310.","journal-title":"Transl Psychiatry"},{"key":"2097_CR74","doi-asserted-by":"crossref","unstructured":"Torrado Pacheco A, Olson RJ, Garza G, Moghaddam B Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology. 2023;48:1011\u201320.","DOI":"10.1038\/s41386-023-01545-z"},{"key":"2097_CR75","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S0893-133X(98)00108-0","volume":"20","author":"FX Vollenweider","year":"1999","unstructured":"Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man\u2014A PET study with [11 C]raclopride. Neuropsychopharmacology. 1999;20:424\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"2097_CR76","doi-asserted-by":"publisher","first-page":"e34687","DOI":"10.1097\/MD.0000000000034687","volume":"102","author":"L-L Jiang","year":"2023","unstructured":"Jiang L-L, Wu Y-L, Mo Y, Gou L, Chen M-L, Wang Y, et al. The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson\u2019s disease: a meta-analysis. Med (Balt). 2023;102:e34687.","journal-title":"Med (Balt)"},{"key":"2097_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/mds.28335","volume":"36","author":"A Takamiya","year":"2021","unstructured":"Takamiya A, Seki M, Kudo S, Yoshizaki T, Nakahara J, Mimura M, et al. Electroconvulsive therapy for Parkinson\u2019s disease: a systematic review and meta\u2010analysis. Mov Disord. 2021;36:50\u201358.","journal-title":"Mov Disord"},{"key":"2097_CR78","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1300\/J018v10n04_03","volume":"10","author":"DP Birkett","year":"1991","unstructured":"Birkett DP. Electroconvulsive therapy and Parkinson\u2019s disease. Clin Gerontol. 1991;10:11\u201322.","journal-title":"Clin Gerontol"},{"key":"2097_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-023-02464-9","volume":"13","author":"SM Szymkowicz","year":"2023","unstructured":"Szymkowicz SM, Gerlach AR, Homiack D, Taylor WD. Biological factors influencing depression in later life: role of aging processes and treatment implications. Transl Psychiatry. 2023;13:1\u201316.","journal-title":"Transl Psychiatry"},{"key":"2097_CR80","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nrneurol.2011.60","volume":"7","author":"AL Byers","year":"2011","unstructured":"Byers AL, Yaffe K. Depression and risk of developing dementia. Nat Rev Neurol. 2011;7:323\u201331.","journal-title":"Nat Rev Neurol"},{"key":"2097_CR81","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.jagp.2016.06.005","volume":"24","author":"PJ Brown","year":"2016","unstructured":"Brown PJ, Rutherford BR, Yaffe K, Tandler JM, Ray JL, Pott E, et al. The depressed frail phenotype: the clinical manifestation of increased biological aging. Am J Geriatr Psychiatry. 2016;24:1084\u201394.","journal-title":"Am J Geriatr Psychiatry"},{"key":"2097_CR82","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1111\/ene.12740","volume":"22","author":"C-H Lin","year":"2015","unstructured":"Lin C-H, Lin J-W, Liu Y-C, Chang C-H, Wu R-M. Risk of Parkinson\u2019s disease following anxiety disorders: a nationwide population-based cohort study. Eur J Neurol. 2015;22:1280\u20137.","journal-title":"Eur J Neurol"},{"key":"2097_CR83","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nrneurol.2010.52","volume":"6","author":"AHV Schapira","year":"2010","unstructured":"Schapira AHV, Tolosa E. Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol. 2010;6:309\u201317.","journal-title":"Nat Rev Neurol"},{"key":"2097_CR84","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/1531-8257(200007)15:4<669::AID-MDS1011>3.0.CO;2-5","volume":"15","author":"M Shiba","year":"2000","unstructured":"Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson\u2019s disease: A case-control study. Mov Disord. 2000;15:669\u201377.","journal-title":"Mov Disord"},{"key":"2097_CR85","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.pnpbp.2018.05.025","volume":"86","author":"S Wang","year":"2018","unstructured":"Wang S, Mao S, Xiang D, Fang C. Association between depression and the subsequent risk of Parkinson\u2019s disease: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;86:186\u201392.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2097_CR86","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1474-4422(21)00330-6","volume":"21","author":"D Weintraub","year":"2022","unstructured":"Weintraub D, Aarsland D, Chaudhuri KR, Dobkin RD, Leentjens AF, Rodriguez-Violante M, et al. The neuropsychiatry of Parkinson\u2019s disease: advances and challenges. Lancet Neurol. 2022;21:89\u2013102.","journal-title":"Lancet Neurol"},{"key":"2097_CR87","doi-asserted-by":"crossref","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020:1\u20139.","DOI":"10.1038\/s41386-020-0718-8"},{"key":"2097_CR88","doi-asserted-by":"crossref","unstructured":"Marek GJ Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons. In: Halberstadt AL, Vollenweider FX, Nichols DE, editors. Behav. Neurobiol. Psychedelic Drugs, Berlin, Heidelberg: Springer; 2018. p. 107-35.","DOI":"10.1007\/7854_2017_480"},{"key":"2097_CR89","doi-asserted-by":"crossref","unstructured":"Flanagan TW, Nichols CD Psychedelics and Anti-inflammatory Activity in Animal Models. In: Barrett FS, Preller KH, editors. Disruptive Psychopharmacol., Cham: Springer International Publishing; 2022. p. 229-45.","DOI":"10.1007\/7854_2022_367"},{"key":"2097_CR90","doi-asserted-by":"crossref","unstructured":"Koz\u0142owska U, Klimczak A, Wiatr K, Figiel M. The DMT and Psilocin Treatment Changes CD11b+ activated microglia immunological phenotype. 2021:2021.03.07.434103.","DOI":"10.1101\/2021.03.07.434103"},{"key":"2097_CR91","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bbi.2023.09.004","volume":"114","author":"NL Mason","year":"2023","unstructured":"Mason NL, Szabo A, Kuypers KPC, Mallaroni PA, de la Torre Fornell R, Reckweg JT, et al. Psilocybin induces acute and persisting alterations in immune status in healthy volunteers: an experimental, placebo-controlled study. Brain Behav Immun. 2023;114:299\u2013310.","journal-title":"Brain Behav Immun"},{"key":"2097_CR92","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0269881120959614","volume":"35","author":"OH Jefsen","year":"2021","unstructured":"Jefsen OH, Elfving B, Wegener G, M\u00fcller HK. Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin. J Psychopharmacol (Oxf). 2021;35:483\u201393.","journal-title":"J Psychopharmacol (Oxf)"},{"key":"2097_CR93","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","volume":"109","author":"L-X Shao","year":"2021","unstructured":"Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535\u20132544.e4.","journal-title":"Neuron"},{"key":"2097_CR94","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharm Sci. 2020;144:151\u2013164.","journal-title":"J Pharm Sci"},{"key":"2097_CR95","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2174\/187152709789824606","volume":"8","author":"KA Johnson","year":"2009","unstructured":"Johnson KA, Conn PJ, Niswender CM. Glutamate receptors as therapeutic targets for Parkinson\u2019s disease. CNS Neurol Disord - Drug Targets- CNS Neurol Disord. 2009;8:475\u201391.","journal-title":"CNS Neurol Disord - Drug Targets- CNS Neurol Disord"},{"key":"2097_CR96","doi-asserted-by":"crossref","unstructured":"Picconi B, Piccoli G, Calabresi P. Synaptic dysfunction in Parkinson\u2019s disease. In: Kreutz MR, Sala C, editors. Synaptic Plast. Dyn. Dev. Dis., Vienna: Springer; 2012. p. 553-72.","DOI":"10.1007\/978-3-7091-0932-8_24"},{"key":"2097_CR97","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey MG, Wallings RL, Houser MC, Herrick MK, Keating CE, Joers V. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22:657\u201373.","journal-title":"Nat Rev Immunol"},{"key":"2097_CR98","doi-asserted-by":"publisher","unstructured":"Aday JS, Heifets BD, Pratscher SD, Bradley E, Rosen R, Woolley JD. Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials. Psychopharmacology (Berl). 2022. https:\/\/doi.org\/10.1007\/s00213-022-06123-7.","DOI":"10.1007\/s00213-022-06123-7"},{"key":"2097_CR99","unstructured":"Lidstone SC. Great Expectations: The Placebo Effect in Parkinson\u2019s Disease. In: Benedetti F, Enck P, Frisaldi E, Schedlowski M, editors. Placebo, Berlin, Heidelberg: Springer; 2014. p. 139-47."},{"key":"2097_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1824-6","volume":"18","author":"TI Michaels","year":"2018","unstructured":"Michaels TI, Purdon J, Collins A, Williams MT. Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature. BMC Psychiatry. 2018;18:245.","journal-title":"BMC Psychiatry"},{"key":"2097_CR101","doi-asserted-by":"crossref","unstructured":"Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:1\u20137.","DOI":"10.1073\/pnas.2022489118"},{"key":"2097_CR102","doi-asserted-by":"crossref","unstructured":"Kozlowska U, Nichols C, Wiatr K, Figiel M. From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem. 2021;00:1\u201320.","DOI":"10.1111\/jnc.15509"},{"key":"2097_CR103","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15544","volume":"162","author":"HN Saeger","year":"2022","unstructured":"Saeger HN, Olson DE. Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem. 2022;162:109\u201327.","journal-title":"J Neurochem"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02097-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02097-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T09:02:17Z","timestamp":1750064537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02097-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2097"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02097-0","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AO has received research support from SILO Inc. and Filament Health. ADP has received research support from the Multidisciplinary Association for Psychedelic Studies (MAPS), Usona Institute, and Filament Health. He has consulted for Tactogen, Osmind, Compass Pathways, Mindmed, and Alexander Shulgin Research Institute. He has served on the advisory boards of Otsuka, Alkermes. He is a shareholder in Tactogen and Osmind. JDW has received research support from Usona Institute and Filament Health. He has consulted for Alexander Shulgin Research Institute, Guidepoint, Magdalena Biosciences,\u00a0Arcadia Medicine, MindMed,\u00a0and Techspert.IO. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}